Profile data is unavailable for this security.
About the company
Shandong Lukang Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development, production and sales of pharmaceutical products. The Company's product portfolio includes antibiotics, antidiabetic agents, cardiovascular and cerebrovascular medications, digestive system drugs, endocrine agents, respiratory system medications, andrological drugs, antiviral agents, amino acid preparations, traditional Chinese patent medicines and simple preparations, semi-synthetic antibiotic raw materials, pharmaceutical intermediates, and antibiotics for animal health. The Company's products cover various specifications such as capsules, tablets, dispersible tablets, powder injections, granules, dry suspensions, aqueous injections, premixes, and compound preparations. The Company conducts its business in the domestic and overseas markets.
- Revenue in CNY (TTM)6.19bn
- Net income in CNY188.75m
- Incorporated1993
- Employees6.39k
- LocationShandong Lukang Pharmaceutical Co LtdNo. 88Deyuan Road, Jining High-Tech ZoneJINING 272000ChinaCHN
- Phone+86 5 372983174
- Fax+86 5 372983097
- Websitehttps://www.lkpc.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harbin Pharmaceutical Group Co Ltd | 15.94bn | 449.15m | 8.69bn | 9.85k | 19.35 | 1.54 | -- | 0.5451 | 0.1783 | 0.1783 | 6.33 | 2.25 | 1.12 | 5.90 | 3.34 | -- | 3.42 | 1.58 | 8.28 | 4.28 | 25.83 | 24.86 | 3.04 | 1.51 | 1.16 | 17.44 | 0.1628 | 0.00 | 4.65 | 6.47 | 59.10 | 62.32 | 20.92 | -- |
| KPC Pharmaceuticals Inc | 7.70bn | 530.05m | 9.31bn | 5.28k | 17.41 | 1.75 | -- | 1.21 | 0.7067 | 0.7067 | 10.21 | 7.01 | 0.6987 | 2.98 | 2.48 | 1,458,805.00 | 6.21 | 5.65 | 11.19 | 9.98 | 41.77 | 43.07 | 8.89 | 6.71 | 1.58 | -- | 0.1981 | 34.63 | -0.3408 | 0.6839 | 19.86 | 7.36 | -25.55 | 8.45 |
| North China Pharmaceutical Co Ltd | 9.79bn | 183.03m | 9.44bn | 10.09k | 51.65 | 1.71 | -- | 0.9635 | 0.1065 | 0.1065 | 5.69 | 3.21 | 0.453 | 2.91 | 4.26 | 970,873.20 | 1.30 | -0.2469 | 3.23 | -0.578 | 30.05 | 33.78 | 2.86 | -0.5243 | 0.4902 | 2.22 | 0.6254 | -- | -2.48 | -2.94 | 2,496.80 | -5.90 | 3.21 | 0.00 |
| Youcare Pharmaceutical Group Co Ltd | 2.55bn | -233.99m | 9.49bn | 3.28k | -- | 2.77 | -- | 3.72 | -0.5306 | -0.5306 | 5.75 | 7.62 | 0.4537 | 2.18 | 4.03 | 777,123.10 | -4.30 | 5.90 | -5.97 | 8.92 | 47.55 | 63.64 | -9.48 | 7.49 | 1.49 | -41.24 | 0.1633 | 66.99 | -9.90 | -2.48 | -33.05 | -15.40 | 19.36 | -- |
| Shandong Lukang Pharmaceutical Co Ltd | 6.19bn | 188.75m | 9.53bn | 6.39k | 43.65 | 2.07 | -- | 1.54 | 0.2089 | 0.2089 | 6.85 | 4.40 | 0.6891 | 3.69 | 6.77 | 969,079.80 | 2.20 | 2.78 | 3.60 | 5.00 | 22.98 | 22.76 | 3.20 | 4.17 | 0.7984 | 6.01 | 0.4324 | 31.07 | 1.41 | 10.80 | 60.30 | 26.62 | -19.55 | 24.01 |
| Chongqing Taiji Industry Group Co Ltd | 10.04bn | -352.52m | 9.69bn | 11.97k | -- | 2.74 | -- | 0.965 | -0.8238 | -0.8238 | 18.98 | 6.42 | 0.7032 | 2.85 | 3.55 | 838,688.20 | -2.36 | 0.9924 | -6.94 | 3.04 | 26.30 | 43.37 | -3.35 | 1.08 | 0.4906 | 0.5756 | 0.5914 | 22.39 | -20.72 | 1.24 | -96.76 | -- | -3.36 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Shanghai HFT Fortune Asset Management Co. Ltd.as of 31 Mar 2025 | 8.80m | 0.99% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 6.66m | 0.75% |
| Aegon-Industrial Fund Management Co., Ltd.as of 31 Mar 2025 | 4.08m | 0.46% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 3.95m | 0.44% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 3.14m | 0.35% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 2.50m | 0.28% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 1.66m | 0.19% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 1.22m | 0.14% |
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2025 | 816.70k | 0.09% |
| Golden Trust Sinopac Fund Management Co., Ltd.as of 30 Jun 2025 | 400.00k | 0.05% |
